Clinical trials: Effect of Drugs
- Condition Effect of Drugs
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Drug Drug Interaction, Healthy
Pharmacokinetics of Omeprazole and Midazolam When Co-administered With ACT-1014-6470
A study on whether ACT-1014-6470 has an effect on how the body takes up, distributes and gets rid of omeprazole and midazolam in healthy male subjects
- Trial name
- NCT05123820
- Testing
- Treatment period A, Treatment period B
- Where
- Czechia
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Fungal Infection
Safety, Pharmacokinetics, Bioavailability, Food Effect, Drug-Drug Interaction Study of APX001 Administered Orally
This is a Phase l double-blind, placebo-controlled, randomized study to investigate the safety, tolerability, pharmacokinetics, bioavailability and food effect of single doses of APX001 administered intravenously and orally…
- Trial name
- NCT02957929
- Testing
- APX001 single IV dose, APX001 single oral dose 1, APX001 single oral dose 2
- Where
- 2 sites in Netherlands
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Basilea Pharmaceutica
Healthy Volunteers
A Study to Evaluate the Effect of Itraconazole and Rifampin on the Drug Levels of AR-LDD (BMS-986365) in Healthy Adult Male Participants
The purpose of this study is to evaluate the effect of Itraconazole and Rifampin on the drug levels of AR-LDD (BMS-986365) in healthy adult male participants.
- Trial name
- NCT07242781
- Testing
- BMS-986365, Itraconazole, Rifampin
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Celgene
Drug-induced Weight Gain
Effect of RDX-002 on Postprandial Triglycerides in Subjects Treated With Olanzapine
This Phase 1b Study RDX-002-22-09 has been planned to evaluate the effect of RDX-002 on postprandial triglycerides and ApoB48 levels in normal healthy subjects treated with the atypical antipsychotic drug, olanzapine.
- Trial name
- NCT05857566
- Testing
- RDX-002 + Olanzipine, Olanzapine
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Response Pharmaceuticals
Healthy Volunteers
Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 3 of 4)
The purpose of this study is to evaluate the ability of PRT064445 to reverse the effects of several blood thinner drugs on laboratory tests. The study also is evaluating the blood levels of PRT064445 given at different doses.
- Trial name
- NCT03551730
- Testing
- PRT064445/Enoxaparin
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Portola Pharmaceuticals
Chronic Obstructive Pulmonary Disease (COPD)
Effect of Cyclosporine Drug Interaction on the Absorption, Metabolism and Elimination of CHF6001 in Healthy Volunteers. Drug-Drug Interaction 2 (DDI2) Study
The main goal of this pharmacokinetic study in healthy volunteers is to evaluate the potential effect of cyclosporine (probe inhibitor of P glycoprotein [P-gp] and breast cancer resistance protein [BCRP] transporters) on CHF6001…
- Trial name
- DDI2 (NCT06892756)
- Testing
- CHF6001 dry powder inhaler (DPI), Cyclosporine, CHF6001 DPI
- Where
- Bulgaria
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Chiesi Farmaceutici S.p.A.
Healthy
A Drug Interaction Study of Cyclosporine and LY3502970 in Healthy Participants
The main purpose of this study is to determine the levels of study drug called LY3502970 in the blood stream when administered alone and in combination with cyclosporine in healthy participants.
- Trial name
- NCT05573230
- Testing
- Midazolam, LY3502970, Cyclosporine
- Where
- Singapore
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy Subjects
To Study And Compare Bioavailability And Safety Of Four Different Formulations Of The Study Drug
SB-742510 is a semi-synthetic pleuromutilin antibiotic that is being developed for treatment of respiratory infections. The purpose of this study is to estimate the bioavailability of four different formulations and to evaluate…
- Trial name
- NCT00436228
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Virus Diseases, RNA Virus Infections
Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in Adults
This Phase 3 study is intended to assess the efficacy of the Quadrivalent VLP Influenza Vaccine during the 2017-2018 influenza season in healthy adults 18 to 64 years of age.
- Conditions
- Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
- Trial name
- NCT03301051
- Testing
- Quadrivalent VLP Vaccine
- Where
- 73 sites in United States, Canada and 5 more
- Volunteers
- 10,160 people, healthy volunteers welcome
- Sponsor
- Medicago
Drug Interaction Study
To Evaluate the Effect of Clarithromycin on the Systemic Exposure of Pacritinib in Healthy Subjects
This will be an open-label, single-center, crossover, one-way, drug-interaction study to evaluate the effect of 500 mg clarithromycin BID (dosed to steady state) on the PK of a single 400-mg dose of pacritinib in healthy male and…
- Trial name
- NCT02807051
- Testing
- Pacritinib, Clarithromycin, Pacritinib and Clarithromycin
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- CTI BioPharma
Healthy
Drug-drug Interaction (DDI) Study to Assess Effect of Itraconazole and Rifampicin Upon Olorofim
This is a Phase 1, single-centre, fixed-sequence, open label, drug-drug interaction study in 2 groups of healthy subjects. Group A: to evaluate the effects of itraconazole, a strong inhibitor of cytochrome P450 3A (CYP3A), upon…
- Trial name
- NCT04171739
- Testing
- Itraconazole oral solution, Rifampicin Oral Capsule, Olorofim
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- F2G Ltd
Health Participants
A Study to Evaluate the Safety, Tolerability, Drug Levels and Drug Effects of Single and Multiple Doses of BMS-986209 in Healthy Participants
The purpose of this study is to investigate the safety and tolerability of BMS-986209 in healthy participants. The first-in-human study is designed in 3 parts that vary based on duration and food effect.
- Trial name
- NCT04154800
- Testing
- BMS-986209, Itraconazole, Diltiazem
- Where
- United States
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Healthy Volunteers
Understanding The Effect Of A Strong CYP3A4 Inducer On Glasdegib Pharmacokinetics
The study also aims to determine the effect of a strong enzyme (CYP3A4) inducer-rifampin- on drug exposure of Glasdegib. This study will be conducted in healthy subjects given a single dose of glasdegib in each period.
- Trial name
- NCT02430545
- Testing
- Glasdegib, Rifampin
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Participants
PF-07321332/Ritonavir and Ritonavir on Dabigatran Study in Healthy Participants
This is a drug-drug interaction study to assess the effects of PF-07321332/ritonavir and ritonavir on the Pharmacokinetic (PK) of dabigatran in healthy volunteers. PK will be evaluated for PF-07321332 and ritonavir.
- Trial name
- NCT05064800
- Testing
- Dabigatran, PF-07321332/ritonavir + Dabigatran, Ritonavir + Dabigatran
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
Drug Interaction Research
Clinical Study on Drug Interactions of Flonoltinib Maleate Tablets
This study is a single center, open label, fixed sequence drug interaction study to evaluate the effects of CYP3A4 inhibitor itraconazole and CYP3A4 inducer rifampicin on the pharmacokinetic characteristics of a single oral dose…
- Trial name
- NCT07768111
- Testing
- 75mg Flonoltinib, 100mg Flonoltinib
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Chengdu Zenitar Biomedical Technology Co., Ltd
Healthy, Obese
A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese Participants
The main purpose of this study is to determine effect of orforglipron capsule formulation on the amount of digoxin, rosuvastatin, acetaminophen, midazolam, and simvastatin (each given alone and together with orforglipron) that…
- Conditions
- Healthy, Obese, Overweight
- Trial name
- NCT06186622
- Testing
- Orforglipron, Simvastatin, Digoxin
- Where
- 2 sites in United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate
The primary objective of the study is to evaluate whether premedication with 325 mg microcoated aspirin (ASA) tablet or a slow-titration dosing schedule of BG00012 reduces the incidence and severity of flushing and GI events…
- Trial name
- NCT01568112
- Testing
- BG00012 (dimethyl fumarate), ASA
- Where
- United States
- Volunteers
- 173 people, healthy volunteers welcome
- Sponsor
- Biogen
Gout
Food Effect Study of Febuxostat XR in Healthy Participants
The purpose of this study is to assess the effect of food on the bioavailability of febuxostat after a single oral dose of 80 mg febuxostat XR and to evaluate the pharmacokinetics (PK) of febuxostat after single oral doses of 40…
- Trial name
- NCT02374164
- Testing
- Febuxostat XR
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Takeda
Drug Absorption
Effect of Gamma-cyclodextrin on the Bioavailability of Ginsenosides
This study will evaluate the relative bioavailability of ginsenosides Rg5, Rk1, and Ck of Red ginseng HRG80 preparations containing gamma-cyclodextrin (GCD) in the blood plasma of healthy subjects after oral administration of two…
- Trial name
- NCT04932265
- Testing
- HRG80™ Red Ginseng, HRG80™ Red Ginseng + gamma cyclodextrin
- Where
- 4 sites in Armenia, Sweden
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- EuroPharma, Inc.
Atherosclerosis
Study to Determine the Effect of Repeated Administration of Diltiazem on the Pharmacokinetics of Darapladib (Sb-480848).
Darapladib (SB-480848) is a novel, selective, orally active inhibitor of lipoprotein associated phospholipase A2 (Lp-PLA2) currently under clinical development by GlaxoSmithKline as a potential anti-atherosclerosis agent for…
- Trial name
- NCT01852565
- Testing
- Darapladib, Diltiazem
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline